Lanadelumab
Lanadelumab is a human monoclonal antibody that targets plasma kallikrein in order to promote prevention of angioedema in patients with hereditary angioedema. In phase 1 clinical trials Lanadelumab was well tolerated and was reported to reduce cleavage of kininogen in the plasma of patients with hereditary angioedema and decrease the number of patients experiencing attacks of angioedema. As of 2017 ongoing trials for Lanadelumab include two phase 3 studies focused on investigating the utility of Lanadelumab in preventing of acute angioedema attacks in hereditary angioedema patients.
This drug was produced by Dyax Corp and currently under development by Shire. Lanadelumab has been designated by the U.S. Food and Drug Administration as a breakthrough therapy.
